Identifying Hypercortisolism in Patients with Resistant Diabetes : Episode 2

Opinion

Video

April 22, 2024

Differentiating Medication Non-Adherence From Underlying Comorbidities

Author(s):

Hanford Yau, MD ,Ralph DeFronzo, MD

The expert panel addresses the common assumption of medication non-adherence in patients with resistant diabetes, provides strategies to differentiate non-adherence from underlying comorbidities contributing to resistance, and discusses the challenges of patients who are post-metabolic surgery, yet experience weight gain and symptom recurrence.

EP: 1.Defining Resistant Diabetes

EP: 2.Differentiating Medication Non-Adherence From Underlying Comorbidities

EP: 3.Barriers to Accessing New Anti-Diabetes Medications

EP: 4.Suspecting Hypercortisolism in Patients With Resistant Diabetes

EP: 5.Testing for Hypercortisolism

EP: 6.Patient Subgroups With a Higher Prevalence of Hypercortisolism

EP: 7.Evolving Perception of Autonomous Adrenal Hypercortisolism

EP: 8.Pathophysiology of Hypercortisolism

EP: 9.Need to Address Underlying Hypercortisolism

EP: 10.Approaching Treatment in Hypercortisolism

EP: 11.Choosing Between Medical and Surgical Options for Hypercortisolism

EP: 12.Long-Term Outcomes for Patients Treated for Hypercortisolism

Related Videos

Achieving Complete Renal Response and Reducing Corticosteroid Use in Lupus Nephritis Treatment With Obinutuzmab, with Richard Furie, MD

Aflibercept 8 mg Shows Durability at 3 Years in Wet AMD with W. Lloyd Clark, MD | Image Credit: Palmetto Retinal Center

Investigating Brensocatib, Potential First Treatment for Bronchiectasis, with James Chalmers, MBChB, PhD

Aflibercept 8 mg Noninferior for RVO in QUASAR with W. Lloyd Clark, MD | Image Credit: Palmetto Retinal Center

AI in Dermatology: Emerging Insights and Diverging Perspectives

Related Content

Related Content

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.